NO20054999L - Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen derav - Google Patents

Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen derav

Info

Publication number
NO20054999L
NO20054999L NO20054999A NO20054999A NO20054999L NO 20054999 L NO20054999 L NO 20054999L NO 20054999 A NO20054999 A NO 20054999A NO 20054999 A NO20054999 A NO 20054999A NO 20054999 L NO20054999 L NO 20054999L
Authority
NO
Norway
Prior art keywords
disorders
tetrahydroquinazoline
methods
myocardial infarction
pyrimidine derivatives
Prior art date
Application number
NO20054999A
Other languages
English (en)
Norwegian (no)
Inventor
Yoshinori Sekiguchi
Kosuke Kanuma
Katsunori Omodera
Tsuyoshi Busujima
Thuy-Ahn Tran
Sangdon Han
Martin Casper
Bryan Kramer
Graerne Semple
Ning Zou
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of NO20054999L publication Critical patent/NO20054999L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • C07D215/42Nitrogen atoms attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
NO20054999A 2003-03-31 2005-10-27 Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen derav NO20054999L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45853003P 2003-03-31 2003-03-31
US49591103P 2003-08-19 2003-08-19
US51018603P 2003-10-09 2003-10-09
US53036003P 2003-12-16 2003-12-16
PCT/JP2004/004624 WO2004087669A1 (en) 2003-03-31 2004-03-31 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof

Publications (1)

Publication Number Publication Date
NO20054999L true NO20054999L (no) 2005-11-07

Family

ID=32854505

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054999A NO20054999L (no) 2003-03-31 2005-10-27 Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen derav

Country Status (13)

Country Link
US (1) US20050197350A1 (de)
EP (1) EP1464335A3 (de)
JP (1) JP2004300156A (de)
KR (1) KR20050118704A (de)
AU (1) AU2004226049A1 (de)
BR (1) BRPI0408910A (de)
CA (1) CA2518913A1 (de)
HK (1) HK1091488A1 (de)
HR (1) HRP20050780A2 (de)
MX (1) MXPA05010475A (de)
NO (1) NO20054999L (de)
TW (1) TW200508202A (de)
WO (1) WO2004087669A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
EP1706384A1 (de) * 2004-01-07 2006-10-04 AstraZeneca AB Therapeutische mittel i
US7230002B2 (en) 2004-02-03 2007-06-12 Glenmark Pharmaceuticals Ltd. Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof
WO2005075426A1 (en) * 2004-02-03 2005-08-18 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
JP2007530445A (ja) * 2004-03-30 2007-11-01 大正製薬株式会社 ピリミジン誘導体及びその使用に関連する治療方法
WO2005110980A2 (en) 2004-04-14 2005-11-24 Amgen, Inc. Aryl sulfones and uses related thereto
WO2006011035A1 (en) * 2004-07-23 2006-02-02 Glenmark Pharmaceuticals Ltd. Novel dipeptidyl peptidase iv inhibitors; process for their preparation and compositions containing them
JP4959569B2 (ja) 2004-10-12 2012-06-27 グレンマーク・ファーマシューティカルズ・エスエー 新規なジペプチジルペプチダーゼiv阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス
EP1831194A4 (de) * 2004-12-21 2009-12-02 Astrazeneca Ab Heterocyclische mchr1-antagonisten und deren verwendung in der therapie
WO2006138304A2 (en) * 2005-06-14 2006-12-28 Taigen Biotechnology Pyrimidine compounds
US8193206B2 (en) * 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
EP1893244A4 (de) * 2005-06-23 2009-06-24 Univ Emory Kontrastmittel
WO2007001958A2 (en) * 2005-06-23 2007-01-04 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
JP2007091649A (ja) * 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
FR2902100A1 (fr) * 2006-06-13 2007-12-14 Sanofi Aventis Sa Molecules duales contenant un derive peroxydique, leur synthese et leurs applications en therapeutique
WO2008105968A1 (en) * 2006-11-03 2008-09-04 Smithkline Beecham Corporation Novel seh inhibitors and their use
US8450336B2 (en) 2006-12-14 2013-05-28 Nps Pharmaceuticals, Inc Use of D-serine derivatives for the treatment of anxiety disorders
KR101599661B1 (ko) * 2007-05-17 2016-03-03 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 이치환된 아미드 화합물
WO2009011336A1 (ja) * 2007-07-18 2009-01-22 Taisho Pharmaceutical Co., Ltd. キノリン化合物
KR101546111B1 (ko) 2007-10-11 2015-08-20 글락소스미스클라인 엘엘씨 신규한 sEH 억제제 및 그의 용도
JP5411867B2 (ja) 2007-10-11 2014-02-12 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規sEH阻害剤およびそれらの使用
US8246752B2 (en) 2008-01-25 2012-08-21 Clear Catheter Systems, Inc. Methods and devices to clear obstructions from medical tubes
WO2009097474A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation Novel seh inhibitors and their use
WO2009097475A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
WO2009097476A1 (en) * 2008-01-30 2009-08-06 Smithkline Beecham Corporation NOVEL sEH INHIBITORS AND THEIR USE
US8273900B2 (en) * 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US8461182B2 (en) * 2008-10-02 2013-06-11 Taisho Pharmaceutical Co., Ltd. 7-piperidinoalkyl-3, 4-Dihydroquinolone derivative
US20140113898A1 (en) * 2010-11-08 2014-04-24 Zalicus Pharmaceuticals Ltd. Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
US9775843B2 (en) 2012-10-11 2017-10-03 Grünenthal GmbH Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders
CN111757739A (zh) 2017-12-13 2020-10-09 普拉西斯生物技术有限责任公司 整合应激反应路径抑制剂
BR112020019595A2 (pt) * 2018-03-29 2021-01-05 Takeda Pharmaceutical Company Limited Composto, e, medicamento.
WO2019236710A1 (en) 2018-06-05 2019-12-12 Praxis Biotech LLC Inhibitors of integrated stress response pathway
AU2020209216A1 (en) 2019-01-18 2021-08-26 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
BR112021014514A2 (pt) * 2019-02-25 2021-09-28 Praxis Biotech LLC Inibidores de via de resposta integrada ao estresse
CA3142748A1 (en) 2019-06-12 2020-12-17 Praxis Biotech LLC Modulators of integrated stress response pathway
WO2021007487A1 (en) 2019-07-11 2021-01-14 Praxis Precision Medicines, Inc. Formulations of t-type calcium channel modulators and methods of use thereof
US10702525B1 (en) * 2019-09-04 2020-07-07 United Arab Emirates University Pyrimidine derivatives as anti-diabetic agents

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9300097B (en) * 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
DE4417163A1 (de) * 1994-05-17 1995-11-23 Hoechst Schering Agrevo Gmbh Heterocyclylamino- und Heterocyclyloxy-cycloalkyl-Derivate, ihre Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
ES2237966T3 (es) * 1998-08-20 2005-08-01 Agouron Pharmaceuticals, Inc. Agentes de gnrh no peptidicos, metodos y compuestos intermedios para su preparacion.
US7101878B1 (en) * 1998-08-20 2006-09-05 Agouron Pharmaceuticals, Inc. Non-peptide GNRH agents, methods and intermediates for their preparation
CA2407149C (en) * 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
TW583185B (en) * 2000-06-13 2004-04-11 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
JP4329290B2 (ja) * 2000-10-06 2009-09-09 田辺三菱製薬株式会社 脂肪族含窒素五員環化合物
AU9419701A (en) * 2000-10-06 2002-04-22 Tanabe Seiyaku Co Aliphatic nitrogenous five-membered ring compounds
JP4329291B2 (ja) * 2000-10-06 2009-09-09 田辺三菱製薬株式会社 含窒素五員環化合物
JP2004524295A (ja) * 2001-01-26 2004-08-12 スミスクライン・ビーチャム・コーポレイション ウロテンシン−ii受容体アンタゴニスト
BR0209932A (pt) * 2001-05-22 2004-10-13 Neurogen Corp Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto
CN1582281A (zh) * 2001-10-01 2005-02-16 大正制药株式会社 Mch受体拮抗剂
IL160874A0 (en) * 2001-10-22 2004-08-31 Tanabe Seiyaku Co 4-imidazolin-2-one derivatives
US7012077B2 (en) * 2001-12-20 2006-03-14 Hoffmann-La Roche Inc. Substituted cyclohexane derivatives
WO2003070244A1 (en) * 2002-02-22 2003-08-28 Abbott Laboratories Antagonist of melanin concentrating hormone and their uses
SE0202134D0 (sv) * 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
CA2518913A1 (en) 2004-10-14
MXPA05010475A (es) 2006-05-25
AU2004226049A1 (en) 2004-10-14
EP1464335A3 (de) 2007-05-09
WO2004087669A1 (en) 2004-10-14
EP1464335A2 (de) 2004-10-06
TW200508202A (en) 2005-03-01
KR20050118704A (ko) 2005-12-19
HK1091488A1 (en) 2007-01-19
US20050197350A1 (en) 2005-09-08
HRP20050780A2 (en) 2009-02-28
BRPI0408910A (pt) 2006-03-21
JP2004300156A (ja) 2004-10-28

Similar Documents

Publication Publication Date Title
NO20054999L (no) Nye quinolin-, tetrahydroquinazolin- og pyrimidinderivater og fremgangsmater for behandling relatert til anvendelsen derav
NO20064950L (no) Pyrimidlnderivater og fremgangsmater for behandling basert pa anvendelse av disse
TW200626152A (en) Pyridine derivatives and pharmaceutical compositions and uses thereof
US8343980B2 (en) Quinazoles useful as modulators of ion channels
CN101903372B (zh) 作为食欲肽受体拮抗剂的杂芳基衍生物
JP5246499B2 (ja) イソキサゾール誘導体及びその使用
JP5857168B2 (ja) ドーパミンd1リガンドとしての複素芳香族化合物およびその使用
KR100932623B1 (ko) 5-ht 수용기에서 활성을 갖는(3,4-다이하이드로-퀴나졸린-2-일)-(2-아릴옥시-에틸)-아민
CY1114165T1 (el) Παραγωγο 7-πιπεριδινοαλκυλ-3,4-διυδροκινολονης
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
HUE033441T2 (en) 4- (Benzyl) piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid hydrolase (phaha) for the treatment of anxiety, pain and other diseases
MY153719A (en) Prokineticin 1 receptor antagonists
NO20072348L (no) Thienopyridinone sammensetninger og fremgangsmate for behandling
Vasbinder et al. Discovery and optimization of a novel series of potent mutant B-RafV600E selective kinase inhibitors
EA200970310A1 (ru) Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht
Tang et al. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors
MX2009005509A (es) 2-aminoquinolina como los antagonistas de los receptores 5-hidroxitriptamina 5a (5-ht5a).
DE602006009804D1 (de) Piperidin-4-yl-amidderivate und ihre verwendung als antagonisten des sst-rezeptors vom subtyp 5
DE502004011551D1 (de) 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen
MX2010009643A (es) Derivados de 2-aminoquinolina como antagonistas del receptor 5-hidroxitriptamina (5a).
NO20092688L (no) Forbindelser med en kombinasjon av cannabinoid-CB1 antagonisme og acetylcholinesteraseinhibering
Gomółka et al. Novel 4-aryl-pyrido [1, 2-c] pyrimidines with dual SSRI and 5-HT1A activity. Part 5
CA2829171A1 (en) Pyrazolidin-3-one derivatives
WO2007069671A1 (ja) 二環式複素環化合物
ATE472538T1 (de) 8-alk0xy-4-methyl-3, 4-dihydr0-chinaz0lin-2-yl- amine und ihre verwendung als 5-ht5a-rezeptor- liganden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application